JPRN-UMIN000006402已完成未知
Multicenter Phase II Study of FOLFOX Plus Bi-weekly Cetuximab as First Line Treatment in Patients with Metastatic Colorectal Cancer - CELINE Trial
Epidemiological and Clinical Research Information Network0 个研究点目标入组 55 人开始时间: 2011年9月26日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •No serious myelosuppression 2)No sensory alteration or paresthesia interfering with function 3)No mental disease or neurovascular disease 4)No radiotherapy to target lesion 5)No severe stenosis by primary lesion 6)No hypersensitivity for test drugs 7)No serious infection 8)No cardiovascular disease, complication 9)No brain metastasis, 10)No large quantity of abdominal or pleural effusion 11)No diarrhea, 12)No active double cancer
研究者
相似试验
已完成
2 期
A Multicenter, Clinical Phase II study of FOLFOXIRI with Bevacizumab As First-line Therapy in Patients with Metastatic Colorectal Cancer.Patients with metastatic colorectal cancer.JPRN-UMIN000013797EPS Corporation65
进行中（未招募）
不适用
Randomized, Phase 2 Study of FOLFOX or FOLFIRI with AG-013736 or Bevacizumab in Patients with Metastatic Colorectal Cancer after Failure of an Irinotecan or Oxaliplatin-containing First-line RegimeSecond line treatment of patients with metastatic carcinoma of colon and rectumMedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerMedDRA version: 9.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticEUCTR2007-006283-30-CZPfizer Inc, 235 East 42nd Street, New York, NY 10017, USA176
进行中（未招募）
不适用
Randomized, Phase 2 Study of FOLFOX or FOLFIRI with AG-013736 or Bevacizumab in Patients with Metastatic Colorectal Cancer after Failure of an Irinotecan or Oxaliplatin-containing First-line RegimeSecond line treatment of patients with metastatic carcinoma of colon and rectumMedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerMedDRA version: 9.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticEUCTR2007-006283-30-BEPfizer Inc, 235 East 42nd Street, New York, NY 10017, USA176
进行中（未招募）
1 期
Randomized, Phase 2 Study of FOLFOX or FOLFIRI with AG-013736 or Bevacizumab in Patients with Metastatic Colorectal Cancer after Failure of an Irinotecan or Oxaliplatin-containing First-line RegimeSecond line treatment of patients with metastatic carcinoma of colon and rectumMedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerMedDRA version: 9.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticEUCTR2007-006283-30-FRPfizer Inc, 235 East 42nd Street, New York, NY 10017, USA176
已完成
2 期
Multicenter Phase II study of modified FOLFOX7(combination chemotherapy of infusional 5-FU/l-Leucovorin and intermittent Oxaliplatin)with bevacizumab in the first-line therapy of colorectal cancer - CRAFT trialadvanced colorectal cancerJPRN-UMIN000002354Epidemiological and Clinical Research Information Network (ECRIN)50